← Oncology Approval Tracker

FDA DECISION ·

Sarclisa Escena + pomalidomide + dexamethasone

subcutaneous isatuximab-irfc with pomalidomide and dexamethasone · Sanofi

FDA approvalNew formulationMultiple myeloma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with multiple myeloma after at least one prior treatment line that included lenalidomide and a proteasome inhibitor.

LAMPGEN ANALYSIS

Why it matters

The subcutaneous route changes administration in this combination. IRAKLIA compared the new route with IV isatuximab and used both response and drug exposure to assess noninferiority.

What research teams should watch

Plan staff training for on-body or manual delivery, administration reactions and documentation of complete dosing. Distinguish the subcutaneous formulation from IV preparation.

PRIMARY RECORDS

Sources